All In Biotech

Drug Trial Radar · NCT04907175

Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

No longer available

Status

No longer available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Sponsor type
Industry
First posted
May 28, 2021

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
Female only, from 18 years, up to 75 years

Summary

As written by the sponsor on the registry.

This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.

Conditions

  • System; Lupus Erythematosus

Interventions

  • HB-adMSCsBiological

    Subject has completed 10 infusions and has been authorized for an additional 12 infusions over 1 year.

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hope Biosciences Stem Cell Research Foundation

    Sugar Land, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.